Roth Capital Increases Nektar Therapeutics (NKTR) Price Target to $31.00

Nektar Therapeutics (NDAQ:NKTR) had its target price boosted by investment analysts at Roth Capital from $23.00 to $31.00 in a report issued on Monday, reports. The firm currently has a “buy” rating on the stock.

Nektar Therapeutics (NDAQ:NKTR) traded up 42.65% during trading on Monday, hitting $22.11. The company had a trading volume of 15,339,226 shares. The stock’s market capitalization is $3.40 billion. The company’s 50 day moving average price is $13.78 and its 200-day moving average price is $14.35. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $22.32.

Your IP Address:

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Stock Target Prices

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *